Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial

NCT03979352 is registered in ClinicalTrials.gov with Samuel Lunenfeld Research Institute, Mount Sinai Hospital as lead sponsor.

NCT NCT03979352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial
Lead sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2019
Completion date
August 31, 2021
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type1 diabetes mellitus